netFormulary

Lancashire and South Cumbria
Formulary

5 Infections

This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net

Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.

Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns.

05-01-01-02 Penicillinase-resistant penicillins

Flucloxacillin

Formulary

Capsules 500mg, 250mg
Liquid 125mg/5mL, 250mg/5mL

Cholestatic jaundice and hepatitis may occur very rarely, up to two months after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. Manufacturer advises:

- flucloxacillin should not be used in patients with a history of hepatic dysfunction associated with flucloxacillin
- flucloxacillin should be used with caution in patients with hepatic impairment
- careful enquiry should be made about hypersensitivity reactions to beta-lactam antibacterials.

Flucloxacillin injection

Formulary

Injection 250mg, 500mg, 1g

Temocillin Negaban^®

Formulary

Injection 1g

Microbiology request only

Links

This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net

Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.

Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns.

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net